Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;27(5):637-41.
doi: 10.1080/09540121.2014.986051. Epub 2014 Nov 28.

Inclusion of trans women in pre-exposure prophylaxis trials: a review

Daniel J Escudero  1 , Thomas Kerr, Don Operario, Maria E Socías, Omar Sued, Brandon D L Marshall
Affiliations
Review

Inclusion of trans women in pre-exposure prophylaxis trials: a review

Daniel J Escudero et al. AIDS Care. 2015.

Abstract

Trans women are at high risk of HIV infection. We conducted a review to determine the extent to which trans women were eligible for inclusion in and enrolled into pre-exposure prophylaxis (PrEP) efficacy trials. Out of seven trials analyzing PrEP efficacy, we found that trans women comprised only 1.2% of one trial and 0.2% of total trial enrollments. Although an additional PrEP trial to determine efficacy among trans women may not be warranted, further research is needed to determine the effectiveness of PrEP in this marginalized population, through observational and feasibility studies. These studies should focus on unique barriers that trans women may experience while obtaining access to PrEP, such as gender discrimination, transphobia, and violence.

Keywords: HIV; PrEP; marginalized population; trans women; transgender.

PubMed Disclaimer

References

    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Celum C. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. doi: 10.1056/NEJMoa1108524. - PMC - PubMed
    1. Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S122–129. doi: 10.1097/QAI.0b013e3182986f69. - PMC - PubMed
    1. Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–222. doi: 10.1016/S1473-3099(12)70315-8. - PubMed
    1. Centers for Disease Control and Prevention Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60(3):65–68. doi: mm6003a1. - PubMed
    1. Centers for Disease Control and Prevention Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2012;61(31):586–589. doi: mm6131a2. - PubMed

Publication types

Substances